Galectin-3 test provides doctors in Europe with new tool for assessing the prognosis of chronic heart failure patient
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partnership with BG Medicine, Inc., (NASDAQ: BGMD) to run on Abbott’s ARCHITECT immunochemistry platform.